Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13144414 | 0.90 | MEN1 (0.52) | MEN1KMT2AHSP90AA1MAPK1ALDH1A1 | |
| SCHEMBL3088463 | 0.89 | HSP90AA1 (0.53) | MEN1KMT2AHSP90AA1TSHRLMNA | |
| SCHEMBL13144416 | 0.89 | CYP3A4 (0.52) | MEN1KMT2AHSP90AA1 | |
| SCHEMBL3093854 | 0.87 | TSHR (0.49) | TSHRMAPK1LMNA | |
| SCHEMBL3099114 | 0.85 | HSP90AA1 (0.49) | MEN1KMT2AHSP90AA1TSHRKDM4E | |
| SCHEMBL3089581 | 0.79 | HPGD (0.50) | HSP90AA1TSHRLMNAALDH1A1HPGD | |
| SCHEMBL3092345 | 0.78 | ALDH1A1 (0.41) | MEN1KMT2ATSHRMAPK1LMNA | |
| SCHEMBL3093720 | 0.78 | HSP90AA1 (0.49) | MEN1KMT2AHSP90AA1TSHRMAPK1 | |
| SCHEMBL3099210 | 0.78 | ADORA3 (0.54) | KMT2AHSP90AA1LMNAKDM4EALDH1A1 | |
| SCHEMBL13144400 | 0.77 | MEN1 (0.60) | MEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | MEN1 4225/4885KMT2A 3779/4885HSP90AA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.